1.03

0.98% +0.01

After Hours: 1.03

IN8bio Inc (INAB)

Overview News Price History Financials Discussions Forecast

IN8bio Inc stock is currently priced at $1.03, with a 24-hour trading volume of 37,482. It has seen a +0.98% increased in the last 24 hours and a +3.00% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.06 pivot point. If it approaches the $0.9633 support level, significant changes may occur.

Previous Close:

$1.02

Open:

$1.04

24h Volume:

37,482

Market Cap:

$45.45M

Revenue:

Net Income/Loss:

$-30.01M

P/E Ratio:

-0.8443

EPS:

-1.22

Net Cash Flow:

$-23.94M

1W Performance:

+1.98%

1M Performance:

+3.00%

6M Performance:

+13.19%

1Y Performance:

-62.95%

1D Range:

$1.02

$1.05

52W Range:

$0.65

$3.48

IN8bio Inc Stock (INAB) Company Profile

Name

IN8bio Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

646 600 6438

Address

350 5th Avenue, Suite 5330, New York

Employee

Twitter

Next Earnings Date

Latest SEC Filings

INAB's Discussions on Twitter

IN8bio Inc Stock (INAB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-30-22	Initiated	H.C. Wainwright	Buy

IN8bio Inc Stock (INAB) Latest News

The Future of IN8bio Inc: Analyzing INAB - The InvestChronicle

The InvestChronicle

IN8bio (NASDAQ:INAB) Price Target Cut to $12.50 - Defense World

Defense World

IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress - GlobeNewswire

GlobeNewswire

IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ... - GlobeNewswire

GlobeNewswire

IN8bio (INAB) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Yahoo Finance

Yahoo Finance

IN8bio Inc Stock (INAB) Financials Data

IN8bio Inc (INAB) Net Income 2024

INAB net income (TTM) was -$30.01 million for the quarter ending December 31, 2023, a -5.21% decrease year-over-year.

IN8bio Inc (INAB) Cash Flow 2024

INAB recorded a free cash flow (TTM) of -$23.94 million for the quarter ending December 31, 2023, a +13.97% increase year-over-year.

IN8bio Inc (INAB) Earnings per Share 2024

INAB earnings per share (TTM) was -$1.01 for the quarter ending December 31, 2023, a +25.74% growth year-over-year.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.